TECHNION – FACULTY OF MEDICINE
March 2010
RESUME
ZAID A. ABASSI, D.Sc.
I.D. number:
Date of birth:
Place of birth:
Family status:
055156178
March 23, 1960
Gush-Halav (Jish), Israel
Married, two children
Phone: (04) 829-5267
Fax: (04) 852-0751
Home address:
32A Dror Street, 31096 Haifa, Israel
ACADEMIC DEGREES
1983 B.Sc. in Biology, Technion-Israel Institute of Technology, Haifa, Israel.
1986 M.Sc. in Medical Sciences, Technion-Israel Institute of Technology, Haifa, Israel.
1989 D.Sc. in Medical Sciences, Technion-Israel Institute of Technology, Haifa, Israel.
ACADEMIC APPOINTMENTS
2007-present Associate professor, Department of Physiology and Biophysics,
Bruce Rappaport Faculty of Medicine, Technion-Israel Institute
of Technology, Haifa, Israel.
2003-2006
Senior lecturer, Department of Physiology and Biophysics,
Bruce Rappaport Faculty of Medicine, Technion-Israel Institute
of Technology, Haifa, Israel.
1995-2003
Adjunct Senior lecturer, Department of Physiology and
Biophysics, Bruce Rappaport Faculty of Medicine, TechnionIsrael Institute of Technology, Haifa, Israel.
PROFESSIONAL EXPERIENCE
Zaid A. Abassi, D.Sc.
2
1995-present Vascular Research Laboratory Director, Department of Vascular Surgery,
Rambam Medical Center, Haifa, Israel.
1992-1995
Visiting Research Associate, Hypertension-Endocrine Branch, National Heart,
Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland,
USA (Topic: molecular physiology of hypertension).
1990-1992
Visiting Postdoctoral Research Fellow, Hypertension-Endocrine Branch,
National Heart, Lung, and Blood Institute, National Institutes of Health,
Bethesda, Maryland (Topic: molecular physiology of hypertension).
RESEARCH INTERESTS
1.
2.
3.
4.
Mechanisms of sodium/water retention and cardiac hypertrophy in congestive
heart failure.
Involvement of the endothelin and nitric oxide systems in the pathogenesis of
hypertension and diabetes.
Pathogenesis of proteinuria in experimental models of nephrotic syndrome:
Novel therapeutic approaches.
Adverse renal effects of pneumoperitoneum: Mechanisms and therapeutic
approaches
TEACHING EXPERIENCE
Renal and Gastrointestinal Physiology (3rd-year medical students).
Renal physiology and the Endocrine System (1st year Nursing students).
Endocrinology (1st year Occupational Therapy students).
Pharmacology of the renin angiotensin aldosterone system (Course: Chapters in
Pharmacology, and TeAMS Pharmacology)
Course Director for Physiology-2 for Medical Students (3rd year), and Physiology for Nursing
students (1st year) since 2000. This includes oral lecturing, responsibility for laboratories and
updating the internet course site.
PUBLIC PROFESSIONAL ACTIVITIES
1992-1995
1993-present
1997-1998
1994-present
Reviewer for Metabolism.
Reviewer for Hypertension.
Reviewer for Clinical and Investigative Medicine
Reviewer for American Journal of Physiology
Zaid A. Abassi, D.Sc.
1997-present
2003-present
2004-present
2005-present
2006-present
2007-present
2007-present
2008-present
2008-present
2009-present
2010-present
2010-present
3
Reviewer for Cardiovascular Research
Reviewer for Journal of Experimental Pharmacology and Therapeutics
Reviewer for Circulation
Reviewer for Biochemical Pharmacology
Reviewer for British Journal of Pharmacology
Reviewer for The Journal Acta Physiologica
Reviewer for Diabetes
Reviewer for Journal of Pharmacy and Pharmacology
Reviewer for American Journal of Nephrology
Reviewer for Histology and Histopathology
Reviewer for International Journal of Experimental Pathology
Reviewer for American Journal of Kidney Diseases
MEMBERSHIPS IN PROFESSIONAL SOCIETIES
American Society of Hypertension
Israeli Society of Nephrology
HONORS
1989-1990
Lady Davis Fellowship for postdoctoral studies, Department of Physiology and
Biophysics, Technion-Israel Institute of Technology, Haifa, Israel.
1991
Travel grant from Joslin Diabetes Center to 3rd International Symposium on
Hypertension Associated with Diabetes Mellitus, Boston, Massachusetts ,
November 21-23, 1991.
1992
Travel grant from American Society of Hypertension to 7th scientific meeting
of ASH, New York, New York, May 6-10, 1992.
1992
Travel grant from Council for High Blood Pressure Research to 46th annual
Fall Conference and Scientific Sessions of the American Heart Association,
Cleveland, Ohio, September 29-October 2, 1992.
1993
Travel grant from American Society of Pharmacology and Experimental
Therapeutics (ASPET) to Experimental Biology meeting, New Orleans,
Louisiana, March 28-April 1, 1993.
1993
Travel grant from American Society of Hypertension to 8th scientific meeting
of ASH, New York, New York, May 6-10, 1993.
Zaid A. Abassi, D.Sc.
1994
Travel grant from American Society of Hypertension to 9th scientific meeting
of ASH, New York, New York, May 10-14, 1994.
1995
National Institutes of Health Award for Research Excellence.
1999
Israeli Society of Nephrology Award (with Dr. F. Nakhoul) (NIS 10,000).
2002
Commendation for Excellence in Teaching of Physiology from the Technion.
2002-2004
Membership in Rappaport Family Institute for Research in the Medical
Sciences.
2006
Hershel Rich Technion Innovation Award
2000-present Commendation for Excellence in Teaching of Physiology from the Technion
Medical Students’ Association.
STUDENTS AND INSTRUCTION
M.Sc./D.Sc./Ph.D.
1.
Clariss Potlog, M.Sc., 1995.
2.
Federico Pieruzzi, Ph.D., 1994-1995.
3.
Ricardo Aviv, D.Sc., 1995.
4.
Olga Gealekman, Ph.D., 2002.
5.
Bahaa Francis, M.Sc. student, 2004.
6.
Sammar Zeid, M.Sc. student, 2005.
7.
Afif Yaacob, MD/PhD student, 2008.
8.
Kalfon Limor PhD student, 2008.
9.
Niroz Abu-Saleh, M.Sc. student, expected graduation 2009-10.
10.
Ilia Goltsman, PhD/MD student, expected graduation 2010-11.
11.
Rana Basal, M.Sc. student expected graduation 2011.
12.
Micahel Davidson, M.Sc. student expected graduation 2011.
4
Zaid A. Abassi, D.Sc.
M.D. Thesis
1.
Ittai Fattal, M.D., October 2001: The influence of dietary salt on the
expression of endothelin-converting enzyme-1 in the kidney.
2.
Anan Abbasi, M.D., January 2004: Involvement of aldosterone in myocardial
fibrosis in experimental heart failure: Comparison with the contribution of
angiotensin II.
3.
Mahmoud Kial, M.D., September 2004: Effects of the Rho-kinase inhibitor,
Y-27632, on renal function and hemodynamic parameters in rats with
experimental congestive heart failure: Comparison with angiotensin II receptor
antagonist.
4.
Hiba Sheikh, M.D., 2007: Effects of novel antidiuretic hormone receptor
antagonists on renal function and cardiac hypertrophy in rats with
experimental congestive heart failure.
5.
Diana Faaour, M.D., 2009: Effects of Everolimus on Urinary Protein
Excretion in Normal Rats and on Proteinuria in Rats With Adriamcin-Induced
Nephrotic Syndrome
Basic Science Project Supervision for Clinical Residents [Scientific Council for Israel
Medical Association]
1.
Farid Nakhoul, M.D., 1989.
2.
Rafi Gery, M.D., 1989.
3.
Irit Weismann, M.D., 1990.
4.
Moein Abu-Atta, M.D., 1990.
5.
Suheir Assady, M.D., 1998.
6.
Rima Gelman, M.D., 2000.
7.
Ali Yehia, M.D., 2003.
8.
Zoya Kosach, M.D., 2004.
9.
Ronit Tal M.D., 2007. The Effect of Vasopressin (AVP) on Pulmonary Edema
Clearance.
5
Zaid A. Abassi, D.Sc.
6
10.
Samer Khatib, M.D., 2008-9. Renal effects of endothelin inhibitors in normal rats and
animals with experimental pneumoperitoneum.
11.
Gidon Berger, M.D., 2008-9. Effects of sepsis on lung edema clearance.
12.
Nabil Graeeb, M.D., 2010. Effects of pneumoperitoneum on renal function in rats
with CHF.
RESEARCH GRANTS
1995-1998
Israel Ministry of Science ($15,000 per year): Effect of cyclosporine on the
metabolism, excretion, and synthesis of endothelin.
1996-1998
Israel Ministry of Health ($13,000 per year): Involvement of nitric oxide and
endothelin systems on the cyclosporine-induced nephrotoxicity.
1998-1999
Mars-Pittsburgh Fund ($20,000): Role of endothelin in the pathogenesis of
congestive heart failure.
1999-2000
Elias Fund ($10,000): Urinary excretion of endothelin and its receptors: a
potential marker of salt-sensitive hypertensive patients.
1999-2000
SmithKline Beecham, U.S.A. ($25,000): Effect of endothelin
receptor antagonist and ACE inhibitors in experimental
congestive heart failure.
2000-2001
Keren Ezvonot (Estate Fund) (NIS 18,000): Urinary excretion
of endothelin and its receptors: a potential marker of salt
hypertensive patients.
2002-2003
Mars-Pittsburgh Fund ($13,000): Involvement of aldosterone in
myocardial fibrosis in experimental congestive heart failure:
comparison with the contribution of angiotensin II.
2002-2004
Rappaport Institute ($25,000 per year): Role of aldosterone in
myocardial fibrosis in experimental congestive heart failure:
comparison with the contribution of angiotensin II.
2003-2005
Israel Ministry of Science, Culture and Sport (first year: NIS
210,000): New pharmacological approaches for cardiac
protection and treatment using prodrugs of histone deacetylaseinhibitors, antioxidants and anti-inflammatory agents.
Zaid A. Abassi, D.Sc.
7
2004-2005
Israel Ministry of Health (100.000 NIS per year): The systemic- renal
advantage of the blockade of the endothelin system in diabetic hypertensive
rats.
2005-2007
Niedersachsen –Israel Research Cooperation Program (78,000 Euro for two
years) Effects of the Popeye Genes in the Adult Heart Hyperfunction. (German
Partner: Thomas Brand, Ph.D.
2005-2006
Merck-USA ($25,000): Role of novel renin inhibitors in rats with experimental
diabetes mellitus.
2005-2008 German-Israel Foundation-GIF. Mechanisms of gap junction remodeling in
cardiac hypertrophy. 37,500 Euro/year for a three year period.
2006-2007
Horowitz ($150,000)- The cardioprotective efficacy of the propargylamine
derivatives in experimental models of major cardiac pathologies.
2006-2007
Novartis-USA ($55,000)- Effects of Everolimus on Urinary Protein Excretion
in Normal Rats and on Proteinuria in Rats With Adriamycin-Induced Nephrotic
Syndrome.
2007-2008 AMIT-Alfred Mann Institute-Technion ($1,000,000)-Compositions and
Methods for Treatment of Cardiovascular Diseases and Disorders. (Together
with Prof. O. Binah and M. Youdim).
2007-2008 The Israel Institute of Technology; Manlam Office ($4000); The Effects Of
Rasagiline And Its Optical Isomer TVP1022 On Cardiac And Renal Function In
Rats With Experimental Congestive Heart Failure.
2007-2009 Israel Ministry of Health (80.000 NIS per year). Do Lungs Contribute to Lung
Edema Clearance in Heart Failure? (Together with Dr. Zaher Azzam).
2008-2011
Israeli National Academy of Science- (315,000 NIS) - Involvement of
Vasopressin in Pulmonary Edema in Heart Failure: Effects of Novel
Vasopressin Antagonists on Lung Edema Clearance (Together with Dr. Zaher
Azzam).
2009-2010 AMIT-Alfred Mann Institute-Technion ($700,000)- Cardioproective effects of
TVP1022, an optical isomer of rasagiline in cardiac injury. (Together with Prof.
O. Binah and M. Youdim).
2009-2010 The Israeli Industry, Commerce and employment Ministry (2.2 million NIS)Development of new drug: TVP1022, an optical isomer of rasagiline for the
treatment of cardiac injury. (Together with Prof. O. Binah and M. Youdim, Y.
Barak).
Zaid A. Abassi, D.Sc.
8
2009-2012 The Israeli Ministry of Health (300.000 NIS)- Synergistic deleterious effects of
combined hyperlipidemia and hyperglycemia on endothelial dysfunction in
diabetes mellitus: Role of nitric oxide and endothelin systems.
PUBLICATIONS
Theses
1.
M.Sc. thesis: Regulation of steroidogenesis in minces of human placenta incubated in
vitro. Technion-Israel Institute of Technology, Haifa, 1986.
2.
D.Sc. thesis: Cellular mechanisms of renal resistance to atrial natriuretic peptide in
experimental models of congestive heart failure and nephrotic syndrome in the rat.
Technion-Israel Institute of Technology, Haifa, 1989.
Refereed Papers in Professional Journals
Basic Research
1.
Winaver, J., Abassi, Z., Hoffman, A., Better, O.S., and Haramati, A.: In vivo and in
vitro effects of atrial natriuretic factor on cGMP production in rats with experimental
heart failure. Progress in Atrial Peptide Research 3:453-457, 1989.
2.
Abassi, Z., Haramati, A., Hoffman, A., Burnett, J.C., Jr., and Winaver, J.: Effect of
converting-enzyme inhibition on renal response to ANF in rats with experimental
heart failure. Am. J. Physiol. 259:R84-R89, 1990.
3.
Better, O.S., Zinman, C., Reis, D.N., Har-Shai, Y., Rubinstein, I., and Abassi, Z.:
Hypertonic mannitol ameliorates intracompartmental tamponade in model
compartment syndrome in the dog. Nephron 58:344-346, 1991.
4.
Abassi, Z., Burnett, J.C., Jr., Grushka, E., Hoffman, A., Haramati, A., and Winaver,
J.: Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure.
Am. J. Physiol. 261:R858-R864, 1991.
5.
Har-Shai, Y., Silbermann, M., Reis, N.D., Zinman, C., Rubinstein, I., Abassi, Z., and
Better, O.S.: Muscle microcirculatory impairment following acute compartment
syndrome in the dog. Plast. Reconstr. Surg. 89:283-289, 1992.
6.
Abassi, Z., Shuranyi, E., Better, O.S., and Winaver, J.: Effect of atrial natriuretic
factor on renal cGMP production in rats with adriamycin-induced nephrotic
syndrome. J. Am. Soc. Nephrol. 2:1538-1544, 1992.
Zaid A. Abassi, D.Sc.
9
7.
Abassi, Z.A., Powell, J.R., Golomb, E., and Keiser, H.R.: Renal and systemic effects
of urodilatin in rats with high-output heart failure. Am. J. Physiol. 262:F615-F621,
1992.
8.
Grossman, E., Hoffman, A., Armando, I., Abassi, Z., Kopin, I.J., and Goldstein, D.S.:
Sympathoadrenal contribution to plasma dopa (3,4-dihydroxyphenylalanine) in rats.
Clin. Sci. (Lond.) 83:65-74, 1992.
9.
Abassi, Z., Golomb, E., and Keiser, H.R.: Neutral endopeptidase inhibition increases
the urinary excretion and plasma levels of endothelin. Metabolism 41:683-685, 1992.
10.
Abassi, Z.A., Tate, J.E., Golomb, E., and Keiser, H.R.: Role of neutral endopeptidase
in the metabolism of endothelin. Hypertension 20:89-95, 1992.
11.
Abassi, Z.A., Tate, J., Hunsberger, S., Klein, H., Trachewsky, D., and Keiser, H.R.:
Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral
endopeptidase inhibition. Am. J. Physiol. 263:E870-E876, 1992.
12.
Abassi, Z.A., Klein H., Golomb E. and Keiser H.R.: Regulation of the urinary
excretion of endothelin in the rat. Am. J. Hypertens. 6:453-457, 1993.
13.
Abassi, Z.A., Klein, H., Cox, J., and Keiser, H.R.: Bradykinin does not modulate the
natriuretic response to atrial natriuretic factor in rats with aortocaval fistula.
Hypertension 21:966-970, 1993.
14.
Golomb, E., Friedman, E., Abassi, Z.A., Trachewsky, D., and Keiser, H.R.: Rare
renal transcription of the atrial natriuretic factor gene in rats. Demonstration by
polymerase chain reaction. Am. J. Hypertens. 6:867-872, 1993.
15.
Abassi, Z.A., Golomb, E., Bridenbaugh, R., and Keiser, H.R.: Metabolism of
endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase
EC.3.4.24.11. Br. J. Pharmacol. 109:1024-1028, 1993.
16.
Abassi, Z.A., Kelly, G., Golomb, E., Klein, H., Keiser, H.R.: Losartan improves the
natriuretic response to ANF in rats with high-output heart failure. J. Pharmacol Exp.
Ther. 268:224-230, 1994.
17.
Abassi, Z.A., Golomb E., Agbaria R., Roller P.P., Tate J., and Keiser, H.R.:
Hydrolysis of iodine labelled urodilatin by recombinant neutral endopeptidase
EC. 3.4.24.11. Br. J. Pharmacol. 113:204-208, 1994.
18.
Golomb, E., Abassi, Z.A., Cuda, G., Stylianou, M., Panchal, V.R., Trachewsky, D.,
and Keiser, H.R: Angiotensin II maintains, but does not mediate, isoproterenolinduced cardiac hypertrophy in rats. Am. J. Physiol. 267:H1496-H1506, 1994.
Zaid A. Abassi, D.Sc.
10
19.
Abassi, Z.A., Kotob, S., Golomb, E., Pieruzzi, F., and Keiser, H.R.: Pulmonary and
renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure.
Hypertension 25:1178-1184, 1995.
20.
Wolfovitz, E., Pacak, K., Abassi, Z., Kopin, I.J., and Goldstein, D.S.: Effects of
hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine
release and synthesis in conscious rats. J. Auton. Nerv. Syst. 54:104-112, 1995.
21.
Pieruzzi, F., Abassi, Z.A., and Keiser, H.R.: Expression of renin-angiotensin system
components in the heart, kidneys, and lungs of rats with experimental heart failure.
Circulation 92:3105-3112, 1995.
22.
Abassi, Z.A., Pieruzzi, F., Nakhoul, F., and Keiser, H.R.: Effects of cyclosporin A on
the synthesis, excretion, and metabolism of endothelin in the rat. Hypertension
27:1140-1148, 1996.
23.
Gurbanov, K., Rubinstein, I., Hoffman, A., Abassi, Z., Better, O.S., and Winaver, J.:
Bosentan improves renal regional blood flow in rats with experimental congestive
heart failure. Eur. J. Pharmacol. 310:193-196, 1996.
24.
Gurbanov, K., Rubinstein, I., Hoffman, A., Abassi, Z., Better, O.S., and Winaver, J.:
Differential regulation of renal regional blood flow by endothelin-1. Am. J. Physiol.
271:F1166-F1172, 1996.
25.
Dekel, B., Nakhoul, F., Abassi, Z., Aviv, R., Winaver, J., and Szylman, P.: Complete
adaptation to chronic potassium loading after adrenalectomy: possible humoral
mechanisms. J. Lab. Clin. Med. 129:453-461, 1997.
26.
Abassi, Z., Kotob, S., Pieruzzi, F., Abouassali, M., Keiser, H.R., Fratantoni, J.C., and
Alayash, A.I.: Effects of polymerization on the hypertensive action of diaspirin crosslinked hemoglobin in rats. J. Lab. Clin. Med. 129:603-610, 1997. [This manuscript
received an editorial comment: J. Lab. Clin. Med. 129:580-583, 1997.]
27.
Abassi, Z.A., Gurbanov., K., Mulroney, S.E., Potlog, C., Opgenorth, T.J., Hoffman,
A., Haramati, A., and Winaver, J.: Impaired nitric oxide-mediated renal vasodilation
in rats with experimental heart failure: role of angiotensin II. Circulation 96:36553664, 1997.
28.
Rubinstein I., Abassi Z., Coleman R., Milman F., Winaver J., and Better O.S.:
Involvement of nitric oxide system in experimental muscle crush injury. J. Clin.
Invest. 101:1325-1333, 1998.
29.
Abassi, Z., Gurbanov, K., Rubinstein, I., Better, O.S., Hoffman, A., and Winaver, J.:
Regulation of intrarenal blood flow in experimental heart failure: role of endothelin
and nitric oxide. Am. J. Physiol. 274:F766-F774, 1998.
Zaid A. Abassi, D.Sc.
11
30.
Abassi, Z., Winaver, J., Rubinstein, I., Shimada, K., Takahashi, M., Tanzawa, K., and
Hoffman, A.: Renal endothelin-converting enzyme in rats with congestive heart
failure. J. Cardiovasc. Pharmacol. 31(Suppl. 1):S31-S34, 1998.
31.
Brodsky, S., Gurbanov, K., Abassi, Z., Hoffman, A., Ruffolo, R.R., Jr., Feuerstein,
G.Z., and Winaver, J.: Effects of eprosartan on renal function and cardiac hypertrophy
in rats with experimental heart failure. Hypertension 32:746-752, 1998.
32.
Hoffman, A., Abassi, Z.A., Brodsky, S., Ramadan, R., and Winaver, J.: Mechanisms
of big endothelin-1-induced diuresis and natriuresis: role of ETB receptors.
Hypertension 35:732-739, 2000.
33.
Green, J., Assady, S., Nakhoul, F., Bick, T., Jakopi, P., and Abassi, Z.: Differential
effects of sera from normotensive and hypertensive pregnant women on Ca2+
metabolism in normal vascular smooth muscle cells. J. Am. Soc. Nephrol. 11:11881198, 2000.
34.
Brodsky, S., Abassi, Z., Wessale, J., Ramadan, R., Winaver, J., and Hoffman, A.:
Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic
responses to endothelin-1. J. Cardiovasc. Pharmacol. 36(Suppl. 1):S311-S313, 2000.
35.
Abassi, Z., Brodsky, S., Gealekman, O., Rubinstein, I., Hoffman, A., and
Winaver, J.: Intrarenal expression and distribution of cyclooxygenase isoforms
in rats with experimental heart failure. Am. J. Physiol. Renal Physiol.
280:F43-F53, 2001.
36.
Goldfarb, M., Abassi, Z., Rosen, S., Shina, A., Brezis, M., and Heyman, S.N.:
Compensated heart failure predisposes to outer medullary tubular injury:
studies in rats. Kidney Int. 60:607-613, 2001.
37.
Abassi, Z.A., Brodsky, S., Karram, T., Dobkin, I., Winaver, J., and Hoffman,
A.: Temporal changes in natriuretic and antinatriuretic systems after closure of
a large arteriovenous fistula. Cardiovasc. Res. 15:567-576, 2001.
38.
Bialik, G.M., Abassi, Z.A., Hammel, I., Winaver, J., and Lewinson, D.:
Evaluation of atrial natriuretic peptide and brain natriuretic peptide in atrial
granules of rats with experimental congestive heart failure. J. Histochem.
Cytochem. 49:1293-1300, 2001.
39.
Gealekman, O., Abassi, Z., Rubinstein, I., Winaver, J., and Binah, O.: Role of
myocardial inducible nitric oxide synthase in contractile dysfunction and adrenergic hyporesponsiveness in rats with experimental volume-overload
heart failure. Circulation 105:236-243, 2002.
Zaid A. Abassi, D.Sc.
12
40.
Abassi, Z., Francis, B., Wessale, J., Ovcharenko, E., Winaver, J., and
Hoffman, A.: Effects of endothelin receptors ETA and ETB blockade on renal
haemodynamics in normal rats and in rats with experimental congestive heart
failure. Clin. Sci. (Lond.) 103(Suppl. 48):245S-248S, 2002.
41.
Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, Reisner SA. Pulmonary
hypertension in patients with end-stage renal disease. Chest. 2003;123(5):1577-82.
42.
Roguin A, Avivi A, Nitecki S, Rubinstein I, Levy NS, Abassi ZA, Resnick MB,
Lache O, Melamed-Frank M, Joel A, Hoffman A, Nevo E, Levy AP. Restoration of
blood flow by using continuous perimuscular infiltration of plasmid DNA encoding
subterranean mole rat Spalax ehrenbergi VEGF. Proc Natl Acad Sci U S A.
2003;100:4644-8.
43.
Roguin A, Nitecki S, Rubinstein I, Nevo E, Avivi A, Levy NS, Abassi ZA, Sabo E,
Lache O, Frank M, Hoffman A, Levy AP. Vascular endothelial growth factor (VEGF)
fails to improve blood flow and to promote collateralization in a diabetic mouse
ischemic hindlimb model. Cardiovasc Diabetol. 2003; 2:18-22.
44.
Nakhoul F, Abassi Z, Plawner M, Khankin E, Ramadan R, Lanir N, Brenner B, Green
J. Comparative study of response to treatment with supraphysiologic doses of Bvitamins in hyperhomocysteinemic hemodialysis patients. Isr Med Assoc J. 2004;
6:213-7.
45.
Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective
and potent inhibitor of mitochondrial monoamine oxidase B: comparison with
selegiline. Br J Pharmacol. 2004;143:371-8.
46.
Fattal I, Abassi Z, Ovcharenko E, Shimada K, Takahashi M, Hoffman A, and Winaver
J. Effect of dietary sodium intake on the expression of endothelin converting enzyme
in the renal medulla. Nephron, 98:89-96, 2004.
47.
Abassi ZA, Yahia A, Zeid S, Karram T, Golomb E, Winaver J, Hoffman A. Cardiac
and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental
congestive heart Failure. Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H722-8.
48.
Francis B.N., Abassi Z., Heyman S., Winaver J., and Hoffman A. Differential
Regulation of ETA and ETB in the Renal Tissue of Rats with Compensated and
Decompensated Heart Failure. J. Cardiovasc. Pharmacol. 44 (Suppl 1): S362- S365,
2004.
49.
Francis B.N., Winaver J., Karram T., Hoffman A., and Abassi ZA. Renal and
Systemic Effects of Chronic Blockade of ETA or ETB Receptors in Normal Rats and
Animals with Experimental Heart Failure. J. Cardiovasc. Pharmacol. 44 (Suppl 1):
S54- S58, 2004.
Zaid A. Abassi, D.Sc.
13
50.
Hoffman C., Francis BN, Rosenthal T, Winaver J, Rubinstein I, and Abassi Z.
Effects of Endothelin-1 on Systemic and Renal Hemodynamics in HypertensiveDiabetic Rats (CRDH), Diabetic Rats (CDR), and Hypertensive Rats (SHR). J.
Cardiovas. Pharmacol. 44 (Suppl 1): S191-S194, 2004.
51.
Nakhoul F, Yigla M, Gilman R, Reisner S A, Abassi Z. The pathogenesis of
pulmonary hypertension in hemodialysis patients via arterio-venous access.
Nephrology Dialysis and Transplantation. Nephrol. Dial. Transplant. 2005 20: 16861692.
52.
Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, Hoffman A,
Abassi Z. Effects of Spironolactone and Eprosartan on Cardiac Remodeling and
Angiotensin Converting Enzyme Isoforms in Rats with Experimental Heart Failure.
Am J Physiol Heart Circ Physiol. 2005; 289:H1351-8.
53.
Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, and
Abassi Z. Glomerular abundance of nephrin and podocin in experimental nephrotic
syndrome: different effects of anti-proteinuric therapies. Am J Physiol Renal Physiol.
2005;289:F880-90.
54.
Barac YD, Zeevi-Levin N, Yaniv G, Reiter I, Milman F, Shilkrut M, Coleman R,
Abassi Z, Binah O. The 1,4,5-inositol trisphosphate pathway is a key component in
Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res.
2005;68:75-86.
55.
Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry
R, Abassi Z. Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting
Enzyme 2 Activity in Congestive Heart Failure Patients. Circ Res. 2005; 28;97:94653.
56.
Nakhoul F, Ramadan R, Maron M, Abassi Z. Post-splenectomy pseudohyperkalemia
in a patient with chronic idiopathic myelofibrosis and thrombocytosis. Clin Nephrol.
2005, 64:243-6.
57.
Karram T, Hoffman A, Bishara B, Brodsky S, Golomb E, Winaver J, Abassi Z.
Induction of cardiac hypertrophy by a controlled reproducible sutureless aortocaval
shunt in the mouse. J Invest Surg. 2005; 18(6):325-34.
58.
Schwarz, H, Abassi Z, Nitecki S, Karram T, Engel A, Ofer A, and Hoffman A.
Thrombolytic Therapy in Ischemic Limbs: Is it a Worthwhile Therapeutic Option?
International Journal of Angiology.14:15-21; 2005.
Zaid A. Abassi, D.Sc.
14
59.
Winaver J, Ovcharenko E, Rubinstein I, Gurbanov K, Pollesello P, Bishara B,
Hoffman A, Abassi Z. Involvement of Rho-kinase pathway in the mechanism of renal
vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. Am J
Physiol Heart Circ Physiol 290: H2007-H2014, 2006.
60.
Ovcharenko E, Abassi Z, Rubinstein I, Kaballa A, Hoffman A, and Winaver J. Renal
effects of human urotensin-II in rats with experimental congestive heart failure.
Nephrol. Dial. Transplant. 21: 1205-1211; 2006.
61.
Nakhoul F., Abassi Z., Morgan M., Sussan S. and Mirsky N. Inhibition of Diabetic
Nephropathy in Rats by an Oral Antidiabetic Material Extracted from Yeast. J Am
Soc Nephrol 17: 127-131, 2006.
62.
Azzam ZS, Adir Y, Welch L, Chen J, Winaver J, Factor P, Krivoy N, Hoffman A,
Sznajder JI, Abassi Z. Alveolar fluid reabsorption is increased in rats with
compensated heart failure. Am J Physiol Lung Cell Mol Physiol.
2006;291(5):L1094-100.
63.
Goldfarb M, Rosenberger C, Abassi Z, Shina A, Zilbersat F, Eckardt KU, Rosen S,
Heyman SN. Acute-on-chronic renal failure in the rat: functional compensation and
hypoxia tolerance. Am J Nephrol. 2006;26 (1):22-33.
64.
Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty
infiltration and improves hepatic fibrosis in obese patients with non-alcoholic
steatohepatitis. Gut. 2007;56 (3):443-4.
65.
Rosenberger C, Khamaisi M, Abassi Z, Shilo V, Weksler-Zangen S, Goldfarb M,
Shina A, Zibertrest F, Eckardt KU, Rosen S, Heyman SN. Adaptation to hypoxia in
the diabetic rat kidney. Kidney Int. 2008 Jan;73(1):34-42. Epub 2007 Oct 3.
66.
Nakhoul F., Khankin E., Yaccob A., Kawachi H. , Karram T, Awaad H., Nakhoul N,
Hoffman A., and Abassi Z. Eplerenone potentiates the anti-proteinuric effects of
enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol.
Mar;294(3):F628-37, 2008. Epub 2007 Dec 19.
67.
Abassi ZA., Bishara B., Karram T., Khatib S., Winaver J., and Hoffman A..
Adverse effects of pneumoperitoneum on renal function: Involvement of the
endothelin and nitric oxide systems. Am J Physiol Regul Integr Comp Physiol
294: R842-R850, 2008. Epub 2007 Dec 26.
68.
Khamaisi M, Raz I, Shilo V, Shina A, Rosenberger C, Dahan R, Abassi Z, Meidan R,
Lecht S, Heyman SN. Diabetes and radiocontrast media increase endothelin converting
enzyme-1 in the kidney. Kidney Int. 2008 Jul;74(1):91-100.
Zaid A. Abassi, D.Sc.
15
69.
Bishara B, Shiekh H, Karram T, Rubinstein I, Azzam Z, Abu-Saleh N, Nitecki S,
Winaver J, Hoffman A, Abassi Z. Effects of novel vasopressin receptor antagonists on
renal function and cardiac hypertrophy in rats with experimental congestive heart
failure. J Pharmacol Exp Ther. 2008 Aug;326(2):414-22.
70.
Asleh R, Blum S, Kalet-Litman S, Alsheik J, Miller-Lotan R, Asaf R, Rock W,
Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction
in individuals with Diabetes and the Haptoglobin 2-2 genotype. Diabetes. 2008
Oct;57(10):2794-800.
71.
Reisner Y, Meiry G, Zeevi-Levin N, Barac DY, Reiter I, Abassi Z, Ziv N, Kostin S,
Shaper J, Rosen MR, Binah O. Impulse conduction and gap junctional remodeling by
endothelin-1 in cultured neonatal rat ventricular myocytes. J Cell Mol Med. 2008 May
9. [Epub ahead of print].
72.
Elkouby-Naor L, Abassi Z, Lagziel A, Gow A, Ben-Yosef T. Double gene deletion
reveals lack of cooperation between claudin 11 and claudin 14 tight junction proteins.
Cell Tissue Res. 2008 Sep;333(3):427-38.
73.
Bishara B., Karram T., Khatib S., Ramadan R., Schwartz H. , Hoffman A., and
Abassi Z. Impact of Pneumoperitoneum on Renal Perfusion and Excretory
Function: Beneficial Effects of Nitroglycerine. Surg Endosc. 2009
Mar;23(3):568-76.
74.
Rubinstein I, Abassi Z., Milman F, Ovcharenko E, Coleman R, Winaver J, and Better
OS. Hyperbaric oxygen treatment improves GFR in rats with ischaemia/reperfusion
renal injury: a possible role for the antioxidant/oxidant balance in the ischaemic
kidney. Nephrol. Dial. Transplant. 2009; 24: 428-436.
75.
Khamaisi M, Dahan R, Hamed S, Abassi Z, Heyman SN, Raz I. Role of protein kinase
C in the expression of endothelin converting enzyme-1. Endocrinology.2009, 150:
1440-9.
76.
Reisner Y, Meiry G, Zeevi-Levin N, Barac DY, Reiter I, Abassi Z, Ziv N,
Kostin S, Schaper J, Rosen MR, Binah O. Impulse conduction and gap
junctional remodelling by endothelin-1 in cultured neonatal rat ventricular
myocytes. J Cell Mol Med. 2009 Mar;13:562-73.
77.
Sukhotnik I, Shaoul R, Lieber M, Coran AG, Abassi Z, Shiloni E, Mogilner JG.
Bilirubin Impairs Intestinal Regrowth Following Massive Small Bowel Resection in a
Rat Model. J Pediatr Gastroenterol Nutr. 2009; 49:16-22.
78.
Haick H, Hakim M, Patrascu M, Levenberg C, Shehada N, Nakhoul F, Abassi Z.
Sniffing Chronic Renal Failure in Rat Model by an Array of Random Networks of
Single-Walled Carbon Nanotubes. ACS Nano. 2009 May 26;3:1258-66.
Zaid A. Abassi, D.Sc.
16
79.
Karram T., Khamaisi M., Bishara B., Ramadan R., Nitecki S., Ben-Izhak O.,
Meretyk S., Winaver J., Heyman S. N., Hoffman A., Abassi Z. Urinary
excretion of endothelin receptors ETA and ETB in hypertensive patients and
normotensive subjects. Kidney Blood Press Res. 2009;32(4):293-303.
80.
Bishara B., Ramadan R, Karram T., Awad H., Abu-Saleh N, Winaver J, Assadi A.,
and Abassi Z. Nitric oxide synthase inhibition aggravates the adverse renal effects of
high, but not low, intra-abdominal pressure. Surg Endosc. 2010; 24:826–833.
81.
Gal S, Abassi ZA, Youdim MB. Limited Potentiation of Blood Pressure in
Response to Oral Tyramine by the Anti-Parkinson Brain Selective
Multifunctional Monoamine Oxidase-AB Inhibitor, M30.Neurotox Res. 2009
Nov 6. [Epub ahead of print].
82.
Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, Roguin A.
Hyperglycemia and Oxidized-LDL exert a deleterious effect on Endothelial
Progenitor Cell migration in Type 2 Diabetes Mellitus. Thromb Res. 2010 Mar
25. [Epub ahead of print]
Clinical Research
1.
Klein, H., Abassi Z., and Keiser, H.R.: Effects of angiotensin II and
phenylephrine on urinary endothelin in normal female volunteers. Metabolism
44:115-118, 1995.
Review Papers and Chapters in Books
2.
Abassi, Z. and Winaver, J.: Atrial natriuretic factor (ANF)—physiological
aspects. Harefuah 115:296-300, 1988 (in Hebrew).
3.
Abassi, Z., Winaver, J., Gery, R., and Better, O.S.: Pathophysiology of atrial
peptides actions. Harefuah 118:31-36, 1990 (in Hebrew).
4.
Better, O.S., Abassi, Z., Rubinstein, I., Marom, S., Winaver, J., and
Silbermann, M.: The mechanism of muscle injury in the crush syndrome:
ischemic versus pressure-stretch myopathy. Miner. Electrolyte Metab. 16:181184, 1990.
5.
Abassi, Z., Winaver, J., Hoffman, A., and Better, O.S.: Endothelin: a new
vasoconstrictor of endothelial origin. Harefuah 120:388-392, 1991 (in
Hebrew).
6.
Abassi, Z., Klein H., Cox, J., and Keiser, H.R.: Urodilatin: a new hormone of
renal origin. Cardiovasc. Drug Rev. 10:199-210, 1992.
Zaid A. Abassi, D.Sc.
7.
Abassi, Z.A., Klein, H., Golomb, E., and Keiser, H.R.: Urinary endothelin: a
possible biological marker of renal damage. Am. J. Hypertens. 6:1046-1054,
1993.
8.
Winaver, J., Hoffman, A., Abassi, Z.A., and Haramati, A.: Does the heart’s
ANP help in congestive heart failure? News Physiol. Sci. 10:247-253, 1995.
[Invited and reviewed].
9.
Abassi, Z.A., Hoffman, A., and Better, O.S.: Acute renal failure complicating
muscle crush injury. Semin. Nephrol. 18:558-565, 1998.
10.
Winaver, J., Abassi, Z., Green, J., and Skorecki, K. Control of extracellular
fluid volume and pathophysiology of edema formation. In The Kidney, 6th
edition, edited by B. Brenner. Philadelphia: W. B. Saunders, 1999, chapter 19,
pp. 795-865, (Invited Chapter).
11.
Green, J., Abassi, Z., Winaver, J., and Skorecki, K.L. Acute renal failure:
clinical aspects and pathophysiologic aspects. In The Kidney: Physiology and
Pathophysiology, 3rd edition, edited by D. Seldin and G. Giebisch.
Philadelphia: Lippincott Williams & Wilkins, 2000, chapter 84, pp. 23292373, (Invited Chapter).
12.
Abassi, Z., Hoffman, A., and Nakhoul, F.: Aquaporins (water channels):
physiology and pathophysiology. Harefuah 138:488-494, 2000 (in Hebrew).
13.
Ellahham, S.H., Charlon, V., Abassi, Z., Calis, K.A., and Choucair, W.K.:
Bosentan and the endothelin system in congestive heart failure. Clin. Cardiol.
23:803-807, 2000. (Invited and reviewed).
14.
Abassi, Z.A., Ellahham, S., Winaver, J., and Hoffman, A.: The intrarenal
endothelin system and hypertension. News Physiol. Sci. 16:152-156, 2001.
[Invited and reviewed].
15.
Karram, T., Hoffman, A., Abbasi, A., and Abassi, Z.: Aldosterone—classic
and non classic effects. Harefuah 141:544-541, 2002 (in Hebrew).
16.
Abassi, Z., Winaver, J., and Skorecki, K.: Control of extracellular fluid
volume and pathophysiology of edema formation. In The Kidney, 7th edition,
edited by B. Brenner. Philadelphia: W. B. Saunders, 2003, chapter 19, pp. 777855,2003, (Invited Chapter).
17.
Winaver, J., Behr, T.M., and Abassi, Z. Role of chemokines in the
pathogenesis of congestive heart failure. In Inflammation and Cardiac
Diseases, series editor M.J. Parnham. Basal: Birkhäuser Verlag AG, 2003, pp.
351-367, (Invited Chapter).
17
Zaid A. Abassi, D.Sc.
18.
Abassi Z, Winaver J, and Hoffman A. LARGE A-V FISTULA:
PATHOPHYSIOLOGICAL CONSEQUENCES AND THERAPEUTIC
PERSPECTIVES. Current Vascular Pharmacology, 1:347-354, 2003.
19.
Abassi Z., Ramadan R., Schwartz H., Hoffman A. Therapeutic implications
of endothelin antagonists for cardiovascular diseases. Harefuah 143:47-53,
2004.
20.
Zaid Abassi, Tony Karram, Samer Ellahham, Joseph Winaver and Aaron
Hoffman. Implications of the Natriuretic Peptide System in the Pathogenesis
of Heart Failure: Diagnostic and Therapeutic Importance. Pharmacology and
Therapeutics. 102:223-241, 2004. [Invited and reviewed].
21.
Zaid Abassi, Bishara Bishara, Afif Yaccob, Aaron Hoffman. Vasopressin V2
receptor antagonists: Pharmacological properties and clinical implications.
Harefuah. 144:875-880, 2005.
22.
Winaver J., Abassi Z.: Role of neuropeptide Y in the regulation of kidney
function. EXS. (95):123-32; 2006.
23.
Abassi Z., Nakhoul F., Khankin E., Reisner S. A., and Yigla M. Pulmonary
hypertension in chronic dialysis patients with arteriovenous fistula:
pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens.
15:353-360; 2006.
24.
Yigla M., Abassi Z., Reisner S.A., Nakhoul F. Pulmonary hypertension in
hemodialysis patients: an unrecognized threat. Seminars in Dialysis. 19:353358; 2006.
25.
Blum S, Nakhoul F, Khankin E, Abassi Z. Renal slit diaphragm--the open
zipper and the failing heart. Isr Med Assoc J; 9:107-11, 2007.
26.
A.H. Abbasi, R. Ramadan, A. Hoffman and Z. Abassi. Kidney-Ear Axis. Isr
Med Assoc J, 9: 814-818; 2007.
27.
Skorecki, K., Winaver, J. Abassi, Z.: Control of extracellular fluid volume and
pathophysiology of edema formation. In The Kidney, 8th edition, edited by B.
Brenner. Philadelphia: W. B. Saunders, 2008, chapter 19, pp. 398-458.
(Invited Chapter).
28.
Hochberg I, Abassi Z, Azzam ZS. Patterns of alveolar fluid clearance in heart
failure. Int J Cardiol. 2008 Nov 12;130(2):125-30.
29.
Abassi Z, Armaly Z, Nakhoul F, Hoffman A. Oral inhibitors of renin and their
potential use as therapeutic agents in treating hypertension. Harefuah.
2008;147:536-42.
18
Zaid A. Abassi, D.Sc.
30.
19
Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin
inhibitors: Implications for translational medicine in hypertension, diabetic
nephropathy and heart failure: Expectations and reality. Biochem Pharmacol.
2009 Oct 15;78(8):933-40.
Case Reports
31.
Nakhoul, F., Green, J., Abassi, Z.A., and Carter, A.: Tumor lysis syndrome
induced by fludarabine monophosphate: A case report [Letter]. Eur. J.
Haematol. 56:254-255, 1996.
32.
Nakhoul F., Abassi, Z., Michaeal M., Khankin E. Post-Splenectomy
pseudohyperkalemia in a patient with chronic idiopathic myelofibrosis and
thrombocytosis–A Case Report. Clin. Nephrol. 2005;64:243-6.
Other Publications
33.
Hoffman, A., Grossman, E., Abassi, Z.A., and Keiser. H.R.: Renal endothelin
and hypertension [Letter; comment on Nature 368:703-710, 1994]. Nature 372:50,
1994.
34.
Abassi Z.A.: Review of book Atrial Natriuretic Factor, edited by A.D.
Struthers (Oxford: Blackwell, 1990; 256 pp.) Cardiovasc. Res. 27: 2287-2288, 1993.
Other Publications
1.
Hoffman, A., Grossman, E., Abassi, Z.A., and Keiser. H.R.: Renal endothelin and
hypertension [Letter; comment on Nature 368:703-710, 1994]. Nature 372:50, 1994.
2.
Abassi Z.A.: Review of book Atrial Natriuretic Factor, edited by A.D. Struthers
(Oxford: Blackwell, 1990; 256 pp.) Cardiovasc. Res. 27: 2287-2288, 1993.
Patents
1.
Compositions and methods for treatment of cardiovascular disorders and diseases.
Moussa BH Youdim, Ofer Binah, Zaid Abassi, Yaron Barac. Pending.
2.
Renal effects of rasagiline and biological-active derivatives in experimental models of
heart failure and renal ischemia. Zaid Abassi, Moussa Youdim, Ofer Binah. Pending.
Zaid A. Abassi, D.Sc.
3.
Detection and diagnosis of chronic renal failure and kidney related diseases by
electronic nose. Zaid Abassi, Farid Nakhoul, Hossam Haik. Pending.
4.
Therapeutic methods for treating medical conditions associated with endothelial
leakage and type I diabetes. Saher Hamed and Zaid Abassi. Pending .
20
Zaid A. Abassi, D.Sc.
21
CONFERENCES
Plenary or Invited Talks at Conferences
1.
Abassi, Z.: Local renin-angiotensin system in the heart and beneficial effects of its
blockade. Annual meeting of the Israeli Society of Nephrology and Hypertension,
Caesarea, Israel, May 2-4, 2002.
2.
Abassi Z.: The endothelin system in the kidney: effects on renal hemodynamics and
sodium transport. Annual meeting of the Israeli Society of Physiology and
Pharmacology. Ma'ale Hachamisha, October 2, 2003.
3.
Abassi Z.: Endothelin and nitric oxide related mechanisms in hypertension. Annual
meeting of the Israeli Society of Endocrinology. Tel-Aviv, December 10-11, 2003.
4.
Abassi, Z.: Mechanisms and pathophysiology of LVH, and CHF: Role of the reninangiotensin aldosterone system. Annual meeting of the Israeli Society of Nephrology
and Hypertension, Caesarea, Israel, 29.4.2004 -1.5.2004.
5.
Abassi, Z.: How can losartan reduce the risk of cardiovascular disease and stroke
beyond blood pressure control. Emerging New Concepts in the Treatment of
Hypertension and Dyslipidemia. The Israeli Society of Cardiology, Dead Sea, Israel,
10-12 June, 2004.
6.
Abassi Z.: Heart failure, neurohormonal activation, and new pharmacological
therapies. Annual meeting of the Israeli Society of Physiology and Pharmacology.
Ma'ale Hachamisha, September 29, 2005.
7.
Abassi Z.: Influence of renin-angiotensin-aldosterone system and other
vasoactive substances on the vasculature. Annual meeting of the Israeli
Society of Physiology and Pharmacology. Tel-Aviv University, September 18,
2006.
8.
Abassi Z.: Animal Models of Glomerular Diseases. Symposium of Glomerular
Diseases, Israeli Society of Nephrology and Hypertension, September 5th,
2008, Dan Acadia, Herzliya, Israel.
Invited Lectures at Medical Centers
A- International:
1.
Abassi Z: Urodilatin and endothelin: involvement in fluid and blood pressure
homeostasis. Department of Physiology and Biophysics, Howard University,
Washington, DC, May 1992.
Zaid A. Abassi, D.Sc.
2.
Abassi Z: Urodilatin/cardiodilatin: new member of the natriuretic peptides
family. The DuPont Merck Pharmaceutical Company, North Billerica, MA,
February 1992.
3.
Abassi Z: Urodilatin: a new natriuretic peptide of renal origin. Department of
Nephrology, John Hopkins University, Baltimore, MD, February 1993.
4.
Abassi Z: Role of neutral endopeptidase in the development of sodium
retention in congestive heart failure. Department of Cardiology, Temple
University, Philadelphia, PA, October 1994.
5.
Abassi Z: Mechanisms of sodium and water retention in congestive heart
failure. Department of Physiology and Biophysics, Howard University,
Washington, DC, October 1994.
6.
Abassi Z: Renin-angiotensin and endothelin: roles in two renal
pathophysiological models. Department of Physiology and Biophysics,
Georgetown University, Washington, DC, June 1995.
7.
Abassi Z: Regulation of renal blood flow in experimental heart failure: role of
endothelin and nitric oxide. Hypertension-Endocrine Branch, National Heart,
Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, June
1997.
8.
Abassi Z: Regulation of renal and intrarenal blood flow in experimental heart
failure: role of endothelin, nitric oxide and cyclooxygenase. Georgetown
University School of Medicine, Washington, DC, July 2001.
9.
Abassi Z: The cardiorenal axis in experimental heart failure. National Heart,
Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, July
2001.
10.
Abassi Z: Potential Role of Endopeptidase Inhibitors in the Treatment of Heart
Failure and Hypertension. Cardiology Grand Rounds Presentation. Department
of Cardiology, Temple University, Philadelphia, PA, USA, 16.5.2003.
11.
Abassi Z: Vasopeptidase Inhibitors: Benefits and Pitfalls. Merck Research
Laboratories, West Point, Delaware, USA, May 12, 2003.
12.
Abassi Z: The renal endothelin system in health and disease. New York
Medical College, Div. Of Nephrology, Valhalla, NY, November 14, 2005.
13.
Abassi Z: Sniffing renal failure by electronic nose. BIT’s World Congress of
Gene-2009. Theme: March into New Era of Bio-Economy. 1-7 December,
2009, Foshan, China.
22
Zaid A. Abassi, D.Sc.
23
B- Israel
1.
Abassi Z: Nitric oxide in the cardiovascular system. Israeli Society For
Clinical Biochemistry, Tel Aviv, January 21-22, 1997.
2.
Abassi Z: Role of endothelin in congestive heart failure. Fifth annual Nahariya
Update International Meeting, Nahariya, Israel, September 18, 1997.
3.
Abassi Z: Endothelin: physiology and pathophysiology. Department of Internal
Medicine, Tel Hashomer Hospital, Tel Aviv, Israel, March 1998.
4.
Abassi Z: The endothelin system and cardiovascular diseases. Rappaport
Seminar, Rappaport Family Institute for Research in the Medical Sciences,
Haifa, Israel, May 2002.
5.
Abassi Z: Treatment of acute and chronic renal injury. Tissue Injury 1st
Conference, Rambam Medical Center, Haifa, Israel, January 23rd, 2008.
Contributed Talks and Posters (presenting author underlined):
1.
Weissman, I., Abassi, Z., Winaver, J., and Better, O.S.: Studies on the mechanism of
renal resistance to atrial natriuretic factor (ANF) in experimental nephrotic syndrome
(NS). Joint meeting of Gesellschaft für Nephrologie and Israel Nephrology Society,
Jerusalem, Israel, November 2-4, 1988. (Poster).
2.
Winaver, J., Abassi, Z., Hoffman, A., Better, O.S., and Haramati, A.: In vivo and in
vitro effects of atrial natriuretic factor on cGMP production in rats with experimental
heart failure. Third scientific meeting of the American Society of Hypertension,
New York, June 22-24, 1988. (Am. J. Hypertens. 1:129A, 1988). (Poster).
3.
Har-Shai, Y., Silbermann, M., Rubinstein, I., Abassi, Z., and Better, O.S.: Sequelae of
muscle tamponade due to canine model of acute compartment syndrome (CS). Third
Vienna Muscle Symposium, Vienna, Austria, June 21-22, 1990. (Poster).
4.
Abassi, Z., Grushka, E., Haramati, A., Hoffman, A., Burnett, J.C., and Winaver, J.:
ANF-induced increase in cyclic GMP production in rats with experimental heart
failure is attenuated in vivo but not in vitro. Twenty-third annual meeting of the
American Society of Nephrology, Washington, DC, December 2-5, 1990. (J. Am. Soc.
Nephrol. 1:409, 1990). (Poster).
5.
Winaver, J., Abassi, Z., Shuranyi, E., and Better, O.S.: Intact renal cyclic (c) GMP
production in response to ANF in rats with adriamycin (ADR) induced nephrotic
syndrome. Twenty-third annual meeting of the American Society of Nephrology,
Washington, DC, December 2-5, 1990. (J. Am. Soc. Nephrol. 1:644, 1990). (Talk).
Zaid A. Abassi, D.Sc.
24
6.
Abassi, Z., Golomb, E., Gill, J.R., and Keiser, H.R.: Neutral endopeptidase (NEP)
inhibition potentiates the renal response to urodilatin in rats with heart failure.
Twenty-fourth annual meeting of the American Society of Nephrology, Baltimore,
Maryland, November 17-20, 1991. (J. Am. Soc. Nephrol. 2:392, 1991). (Poster).
7.
Abassi, Z., Kelly, G., and Keiser, H.R.: Prolongation of the hypertensive response to
endothelin infusion by either nephrectomy or neutral endopeptidase inhibition.
Twenty-fourth annual meeting of the American Society of Nephrology, Baltimore,
Maryland, November 17-20, 1991. (J. Am. Soc. Nephrol. 2:392, 1991) (Poster).
8.
Abassi, Z., Tate, J., and Keiser, H.R.: Effect of neutral endopeptidase
inhibition on the metabolism of endothelin. Twenty-fourth annual meeting of
the American Society of Nephrology, Baltimore, Maryland, November 17-20,
1991. (J. Am. Soc. Nephrol. 2:392, 1991) (Poster).
9.
Abassi, Z., Golomb, E., and Keiser, H.R.: Effects of urodilatin in rats with highoutput heart failure. Forty-fifth annual Fall Conference and Scientific Sessions,
American Heart Association, Chicago, Illinois, September 24-27, 1991. (Talk).
10.
Abassi, Z., and Keiser, H.R.: Effect of neutral endopeptidase inhibition on the
excretion of endothelin. Forty-fifth annual Fall Conference and Scientific Sessions,
American Heart Association, Chicago, Illinois, September 24-27, 1991. (Poster).
11.
Abassi, Z., Golomb, E., Keiser, H.R., and Marban, L.: High blood pressure in
transgenic mice overexpressing the human insulin gene. Third International
Symposium on Hypertension Associated with Diabetes Mellitus, Boston,
Massachusetts, September 25-27, 1991. (Talk).
12.
Abassi, Z., Golomb, E., Tate, J.E., and Keiser, H.R.: Stimulation of urinary excretion
of endothelin by angiotensin II. Seventh scientific meeting of the American Society of
Hypertension, New York, New York, May 6-10, 1992. (Talk).
13.
Golomb, E., Friedman, E., Abassi, Z.A., Trachewsky, D., and Keiser, H.R.: Renal
transcription of the gene encoding for atrial natriuretic peptide. Seventy-fourth annual
meeting of The Endocrine Society, San Antonio, Texas, June 24-27, 1992. (Talk).
14.
Abassi, Z., Klein, H., and Keiser, H. R.: Effect of neutral endopeptidase (NEP) and
C-ANF receptors on the pharmokinetics of ANF and urodilatin. Forty-sixth annual
Fall Conference and Scientific Sessions, American Heart Association, Cleveland,
Ohio, September 29-October 2, 1992. (Talk).
15.
Abassi, Z., and Keiser, H. R., Bradykinin dose not modulate the natriuretic response
to ANF in rats with heart failure. Forty-sixth annual Fall Conference and Scientific
Sessions, American Heart Association, Cleveland, Ohio, September 29-October 2,
1992. (Poster).
Zaid A. Abassi, D.Sc.
25
16.
Abassi, Z., Golomb E., and Keiser, H. R. Angiotensin II (A-II) blockade by DuP 753
potentiates the renal response to ANF in rats with heart failure. Twenty-fifth annual
meeting of the American Society of Nephrology, Baltimore, Maryland, November 1518, 1992. (Poster).
17.
Abassi, Z., and Keiser, H. R., Losartan, an angiotensin II inhibitor, dramatically
improves sodium balance in rats with heart failure. Experimental Biology meeting.
March 28-April 1, 1993. New Orleans, Louisiana. (Poster).
18.
Abassi, Z., and Keiser, H. R., Neutral endopeptidase (EC. 3.4.24.11) is not endothelin
converting enzyme. Eighth scientific meeting of the American Society of
Hypertension, New York, New York, May 6-10, 1993. (Poster).
19.
Golomb, E., Cuda, G., Abassi, Z., and Keiser, H.R.: Long-term molecular responses
to - and -adrenergic stimuli in the rat heart. Scientific Conference on the Molecular
Biology of the Normal, Hypertrophied, and Failing Heart, Pacific Grove, California,
August 4-8, 1993. (Poster).
20.
Abassi, Z., Golomb E., and Keiser, H. R.: Urodilatin is less susceptible than ANP to
degradation by recombinant neutral endopeptidase (EC.3.4.24.11) (rNEP). Ninth
scientific meeting of the American Society of Hypertension, New York, New York,
May 10-14, 1994. (Poster).
21.
Golomb, E., Cuda, G., Abassi, Z., Trachewsky D., and Keiser, H.R.: Cardiac
responses to chronic stimulation of - and -adrenergic and angiotensin receptors in
rats. Ninth scientific meeting of the American Society of Hypertension, New York,
New York, May 10-14, 1994. (Poster).
22.
Abassi, Z.A., Kotob, S., Golomb, E., Pieruzzi, F., and Keiser, H.R.: Pulmonary and
renal neutral endopeptidase EC 3.4.24.11 in rats with experimental congestive heart
failure. Twenty-seventh annual meeting of the American Society of Nephrology,
Orlando, Florida, October 26-29, 1994. (Poster).
23.
Abassi, Z.A., Pieruzzi, F., and Keiser, H. R.: Effects of cyclosporine A on the
clearance of labeled endothelin in rats. Twenty-seventh annual meeting of the
American Society of Nephrology, Orlando, Florida, October 26-29, 1994. (Poster).
24.
Abassi, Z.A., Pieruzzi, F., and Keiser, H. R.: Effects of cyclosporine A on the
synthesis, excretion, and metabolism of endothelin in the rat. Seventh European
Meeting on Hypertension, Milan, Italy, June 9-12, 1995. (Talk)
25.
Pieruzzi, F., Abassi, Z.A., and Keiser H.R.: Expression of renin-angiotensin system
components in the heart, lung, and kidney of rats with experimental heart failure.
Seventh European Meeting on Hypertension, Milan, Italy, June 9-12, 1995. (Poster)
Zaid A. Abassi, D.Sc.
26
26.
Szylman, P., Nakhoul, F., Dekel, B., Abassi, Z., Winaver, J., and Green, J.:
Adaptation to chronic loading in adrenalectomized rats. Twenty-ninth annual meeting
of the American Society of Nephrology, New Orleans, Louisiana, November 3-6,
1996. (J. Am. Soc. Nephrol. 7:1291, 1996). (Poster)
27.
Assady, S., Abassi, Z., Nakhoul, F., Bick, T., Jakobi, P., and Green, J.: The effects of
sera from women with preeclampsia (PE) and hypertensive non-pregnant women on
intracellular Ca++ and nitric oxide metabolism in normal vascular smooth muscle cells
(VSMC). Twenty-ninth annual meeting of the American Society of Nephrology,
New Orleans, Louisiana, November 3-6, 1996. (J. Am. Soc. Nephrol. 7:1530, 1996).
(Poster).
28.
Abassi, Z., Gurbanov, G., Rubinstein, I., Hoffman, A., Haramati, A., and Winaver, J.:
Intact renal nitric oxide (NO) system in experimental congestive heart failure (CHF).
Twenty-ninth annual meeting of the American Society of Nephrology, New Orleans,
Louisiana, November 3-6, 1996. (J. Am. Soc. Nephrol. 7:1557, 1996). (Poster).
29.
Gurbanov, G., Abassi, Z., Rubinstein, I., Hoffman, A., Better, O.S., and Winaver, J.:
Role of endothelin (ET) system in the mediation of intrarenal hemodynamic
alterations in experimental congestive heart failure (CHF). Twenty-ninth annual
meeting of the American Society of Nephrology, New Orleans, Louisiana, November
3-6, 1996. (J. Am. Soc. Nephrol. 7:1562, 1996). (Poster).
30.
Rubinstein, I., Abassi, Z., Milman, F., Winaver, J., and Better, O.S.: Selective
induction of nitric oxide synthase (NOS) isoforms contributes to vasodilation in crush
syndrome. Twenty-ninth annual meeting of the American Society of Nephrology, New
Orleans, Louisiana, November 3-6, 1996. (J. Am. Soc. Nephrol. 7:1833, 1996).
(Poster).
31.
Levin, M., Abassi, Z., Ben-Izhak, O., Nakhoul, F., and Green, J.: Cyclosporine
induces experimental peritoneal fibrosis: prevention by enalapril and losartan
(angiotensin II receptor antagonist). Twenty-ninth annual meeting of the American
Society of Nephrology, New Orleans, Louisiana, November 3-6, 1996. (J. Am. Soc.
Nephrol. 7:1877, 1996). (Poster).
32.
Rubinstein, I., Abassi, Z., Winaver, J., Better, O.S.: Activation of nitric oxide (NO)
system aggravates the hemodynamic shock in crush syndrome. Symposium on Renal
Electrolyte Metabolism—Physiology and Pathophysiology, Vienna, Austria, June 28,
1997. (Wien. Klin. Wochenschr. - Middle European Journal of Medicine 109:538,
1997). (Talk).
33.
Abassi, Z., Winaver, J., Rubinstein, I., and Hoffman, A.: Expression of endothelin
converting enzyme (ECE) in the kidney of rats with congestive heart failure (CHF).
Fifth International Conference on Endothelin, Kyoto, Japan, September 12-15, 1997.
(Poster).
Zaid A. Abassi, D.Sc.
27
34.
Abassi, Z., Rubinstein, I., Ramadan, R., Brodsky, S., Hoffman, A., and Winaver, J.:
Intrarenal distribution of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 in normal
rats and animals with congestive heart failure. Thirty-first annual meeting of the
American Society of Nephrology, Philadelphia, October 25-28, 1998. (J. Am. Soc.
Nephrol. 9, abstract A1691, 1998.) (Talk).
35.
Abassi, Z., Brodsky, S., Rubinstein, I., Ramadan R, Winaver, J., and Hoffman, A.:
Endothelin B receptor (ETB) mediates the diuretic and natriuretic effects of big
endothelin (BET) in rats. Thirty-first annual meeting of the American Society of
Nephrology, Philadelphia, October 25-28, 1998. (J. Am. Soc. Nephrol. 9, abstract
A2021, 1998.) (Poster).
36.
Rubinstein, I., Abassi, Z., Milman F., Winaver, J., and Better, O.S.:
Involvement of tumor necrosis factor  (TNF) in the expression of inducible
nitric oxide synthase (iNOS) following muscle crush injury (MCI). Thirty-first
annual meeting of the American Society of Nephrology, Philadelphia, October
25-28, 1998. (J. Am. Soc. Nephrol. 9, abstract A2996, 1998.) (Poster)
37.
Hoffman, A., Abassi, Z., Brodsky, S., and Winaver, J.: Mechanisms of bigendothelin-1 induced diuresis and natriuresis: role of ETB receptors. Sixth
International Conference on Endothelin, Montreal, Canada, October 10-13,
1999. (Poster).
38.
Brodsky, S., Abassi, Z., Winaver, J., Wessale, J., and Hoffman, A.: Effects of
A-192621.1, a specific ETB antagonist, on intra-renal hemodynamic responses
to endothelin-1. Sixth International Conference on Endothelin, Montreal,
Canada, October 10-13, 1999. (Poster).
39.
Abassi, Z.A., Winaver, J., Brodsky, S.V., Ramadan, R.M., and Hoffman, A.:
Effects of A-192621.1, a specific ETB antagonist, on intra-renal hemodynamic
responses to endothelin. Thirty-second annual meeting of the American
Society of Nephrology, Miami Beach, Florida, November 1-8, 1999. (J. Am.
Soc. Nephrol. 10:341A, 1999). (Poster)
40.
Abassi, Z.A., Brodsky, S.V., Dobkin, I., Winaver, J., and Hoffman, A.:
Changes in natriuretic and antinatriuretic systems after closure of a large
arteriovenous fistula. Thirty-second annual meeting of the American Society
of Nephrology, Miami Beach, Florida, November 1-8, 1999. (J. Am. Soc.
Nephrol. 10:392A, 1999). (Poster).
41.
Goldfarb, M., Abassi, Z., Darmon, D., Shina, A., Brezis, M., Rosen, S., and
Heyman, S.N.: Heart failure predisposes to hypoxic outer medullary tubular
injury: studies in rats. Thirty-second annual meeting of the American Society
of Nephrology, Miami Beach, Florida, November 1-8, 1999. (J. Am. Soc.
Nephrol. 10:631A, 1999). (Poster).
Zaid A. Abassi, D.Sc.
42.
Levin, M., Abassi, Z.A., Ben-Itzhak, O., and Green, J.: Cyclosporine A (CsA)
alters small bowel structure: a possible mechanism for gastrointestinal (GI)
complications following organ allotransplantation. Thirty-second annual
meeting of the American Society of Nephrology, Miami Beach, Florida,
November 1-8, 1999. (J. Am. Soc. Nephrol. 10:707A, 1999).(Poster).
43.
Nakhoul, F., Yigla, M., Gelman, R., Abassi, Z., and Reisner, S.A.: Pulmonary
hypertension in patients with end-stage renal failure on hemodialysis via
surgically created arteriovenous fistula. Thirty-third annual meeting of the
American Society of Nephrology, Toronto, Canada, October 10-16, 2000. (J.
Am. Soc. Nephrol. 11:192A, 2000. (Talk).
44.
Roguin, A., Nitecki, S., Rubinstein, I., Resnik, M.B., Levy, N.S., Abassi,
Z.A., Lache, O., Hoffman, A., and Levy, A.P.: Successful restoration of blood
flow using continuous infiltration of naked-DNA encoding vascular
endothelial growth factor. Forty-ninth annual scientific meeting of the
American College of Cardiology, Orlando, Florida, March 17-20, 2001.
(Poster).
45.
Roguin, A., Nitecki, S., Rubinstein, I., Resnik, M.B., Levy, N., Abassi, Z.,
Lache, O., Hoffman, A., and Levy, A.P.: Successful restoration of blood flow
using continuous infiltration of naked-DNA encoding vascular endothelial
growth factor. Annual meeting of the Israel Heart Association, Jerusalem,
April 1-3, 2001. (Poster).
46.
Roguin, A., Nitecki, S., Rubinstein, I., Levy, N.S., Abassi, Z.A., Hoffman, A.,
and Levy, A.P.: Gene therapy delivery using continuous perimuscular infusion
of naked-DNA encoding VEGF. Fourth International Meeting on
Interventional Cardiology, London, U.K., June 24-27, 2001. (Poster)
47.
Roguin, A., Nitecki, S., Rubinstein, I., Resnik, M.D., Levy, N.S., Abassi,
Z.A., Lache, O., Beyar, R., Hoffman, A., and Levy, A.P.: A novel method for
gene therapy deliver—continuous perimuscular infusion of naked-DNA
encoding VEGF. Thirty-third congress of the European Society of Cardiology,
Stockholm, Sweden, September 1-5, 2001. (Poster)
48.
Abassi, Z.A., Brodsky, S.V., Winaver, J., and Hoffman, A.: A new model of
cardiac hypertrophy in the mouse. Fifth annual scientific meeting of the Heart
Failure Society of America, Washington, DC, September 9-12, 2001. (J. Card.
Fail. 7(Suppl. 2):24, 2001) (Poster).
49.
Roguin, A., Nitecki, S., Rubinstein, I., Sabo, E., Abassi, Z.A., Frank, M.,
Levy, N.S., Lache, O., Hoffman, A., and Levy, A.P.: Gene therapy using a
novel method of delivery—continuous perimuscular infiltration. Fiftieth
annual scientific meeting of the American College of Cardiology, Atlanta,
Georgia, March 16-20, 2002. (Poster).
28
Zaid A. Abassi, D.Sc.
50.
Roguin, A., Nitecki, S., Rubinstein, I., Sabo, E., Levy, N.S., Abassi, Z.A.,
Lache, O., Hoffman, A., and Levy, A.P. Lack of VEGF benefit in restoring
blood flow in a diabetic hindlimb mouse ischemic model. Annual meeting of
the Israel Heart Association, Tel Aviv, April 23-24, 2002. (Poster).
51.
Abassi, Z., Francis, B., Wessale, J., Ovcharenko, E., Winaver, J., and
Hoffman, A.: Effects of endothelin receptors ETA and ETB blockade on renal
haemodynamics in normal rats and in rats with experimental congestive heart
failure. Seventh International Conference on Endothelin, Edinburgh, Scotland,
September 16-19, 2001. (Clin. Sci. 103(Suppl. 48):245S-248S, 2002).
(Poster).
52.
Abassi Z., Yahia, A., Zeid, S., Hayek, T., Winaver, J., and Hoffman, A.:
Effects of omapatrilat, a vasopeptidase inhibitor, on renal function and cardiac
hypertrophy in rats with experimental heart failure. Thirty-fifth annual meeting
of the American Society of Nephrology, Philadelphia, October 30-November
4, 2002. (J. Am. Soc. Nephrol. 13:514A, 2002). (Poster).
53.
Francis B.N., Abassi Z., Heyman S., Winaver J., and Hoffman A. Differential
Regulation of ETA and ETB in the Renal Tissue of Rats with Compensated and
Decompensated Heart Failure. Proceedings of the eight international
conference on endothelin. Tsukuba, Japan. November 23-26, 2003. (Poster).
54.
Francis B.N., Winaver J., Karram T., Hoffman A., and Abassi ZA. Renal and
Systemic Effects of Chronic Blockade of ETA or ETB Receptors in Normal
Rats and Animals with Experimental Heart Failure. Proceedings of the eight
international conference on endothelin. Tsukuba, Japan. November 23-26,
2003. (Talk).
55.
Hofman C., Francis BN, Rosenthal T, Winaver J, Rubinstein I, and Abassi
Z. Effects of Endothelin-1 on Systemic and Renal Hemodynamics in
Hypertensive-Diabetic Rats (CRDH), Diabetic Rats (CDR), and Hypertensive
Rats (SHR). Proceedings of the eight international conference on endothelin.
Tsukuba, Japan. November 23-26, 2003. (Poster).
56.
Heyman S., Abassi Z., Khamaisi M., Shina A., Goldfarb M., Rosen S.
Diabetes predisposes to Medullary Hypoxia with activation of hypoxia
inducible factors (HIF) and upregulation of endothelin B receptor (ETB).
Thirty-seventh annual meeting of the American Society of Nephrology, St.
Louis, MO, USA, October 27- November 1, 2004. (J. Am. Soc. Nephrol.
15:468A, 2004). (Poster).
29
Zaid A. Abassi, D.Sc.
57.
Karram T., Abbasi A., Winaver J., Hoffman A., and Abassi Z. Early
administration of either spironolactone or eprosartan reduces cardiac
hypertrophy and fibrosis in rats with heart failure: Possible involvement of
ACE and ACE-2. Am. J. Hypertension, Volume 17 (No. 5): 84a, 2004.
(Poster).
58.
Hofman C., Francis B.N., Rosenthal T., Winaver J., Rubinstein I., Ovcharenko
E., Abassi Z.: Effects of Endothelin Receptors ETA and ETB Blockade on
Systemic and Renal hemodynamics in Cohen Rosenthal Hypertensive-Diabetic
Rats. Fifteenth European Meeting on Hypertension. Milan, Italy, June 17-21,
2005. (Journal of Hypertension, 23 (Supplement 2:S248, 205). (Poster).
59.
Nakhoul F., Rawi R., Assady S., Khankin E., Moshe L., Abassi Z. Glomerular
Abundance of Nephrin and Podocin in Experimental Nephrotic Syndrome:
Different Effects of Anti-Proteinuric Therapies. Thirty-Eight annual meeting
of the American Society of Nephrology, Philadelphia, November 10-13, 2005.
(J. Am. Soc. Nephrol. 16:P440, 2005). (Poster).
60.
Rosenberger C., Marina Goldfarb M., Abassi Z., Shina A., Eckardt K.U.,
Rosen S., Heyman S. N: Acute-on-Chronic Renal Failure (RF) in the Rat:
Functional Compensation and Hypoxia Tolerance. Thirty-eight annual meeting
of the American Society of Nephrology, Philadelphia, November 10-13, 2005.
(J. Am. Soc. Nephrol. 16:P288, 2005). (Poster).
61.
Nakhoul F., Khankin E. , Ramadan R., Karam T, Awad H, Yaccob A, and
Abassi Z. Anti-proteinuric effects of Eplerenone , a selective aldosterone
blocker in experimental Nephrotic Syndrome: Correlation with Nephrin and
Podocin abundance. Thirty-nine annual meeting of the American Society of
Nephrology, Saint Diego, November 13-18, 2006. (Poster).
62.
Tal R. Hochberg I, Berger G., Egbariah A., Bishara B., Abassi Z. and Azzam
Z. S.. Role of Vasopressin in Lung Edema Clearance in Rats. To be Presented
in ATS 2007, The International Conference of the American Thoracic Society,
San Francisco, USA, May 18-23, 2007. (Poster)
63.
Abassi Z., Bishara B., Karram T., Khatib S., Winaver J., and Hoffman A.
Adverse effects of pneumoperitoneum on renal function: Involvement of the
endothelin (ET) and nitric oxide (NO) systems. Proceedings of the Tenth
international conference on endothelin. Bergamo, Italy. September 16-20,
2007. (Poster).
64.
Karram T., Bishara B., Nitecki S., Ramadan R., Hoffman A., Abassi Z..
Existence of Immunoreactive Endothelin ETA and ETB Receptors in the Urine
of Normal Volunteers. Proceedings of the Tenth international conference on
endothelin. Bergamo, Italy. September 16-20, 2007. (Oral).
30
Zaid A. Abassi, D.Sc.
31
65.
Karram T., Bishara B., Ramadan R, Abu-Saleh N., Heyman S., Winaver J,
Hoffman A., and Abassi Z. Expression of endothelin ETA and ETB receptor in
human kidney: Possible source of urinary ETA and ETB. Forty one annual
meeting of the American Society of Nephrology, Philadelphia, November 4-9,
2008. (J. Am. Soc. Nephrol. 19: 609A, November 2008). (Poster).
66.
Ramadan R., Faour F., Abu-Saleh N., Torgovicky R., Cohen R., Assady S.,
Winaver J., Nakhoul F., and Abassi Z. Effects of Everolimus on Protein
Excretion in Normal Rats and in Rats with Nephrotic Syndrome. Forty one
annual meeting of the American Society of Nephrology, Philadelphia,
November 4-9, 2008. (J. Am. Soc. Nephrol. 19: 326A, November 2008).
(Poster).
67.
Bishara B., Ramadan R., Karram T., Awad H., Abu-Salah N., Winaver J., and
Abassi Z. Nitric oxide synthase inhibition aggravates the adverse renal effects
of high, but not low intra-abdominal pressure. The 17th International congress
of the European Association of Endoscopic Surgery, June 17-20, 2009,
Prague, Czech Republic, (Karl Storz EAES award for one of six best oral
presentations). (Oral)
68.
Goltsman I., Wang X., Ovcharenko E., Feuerstein G., Abassi Z., Winaver J.
Rosiglitazone Improves Natriuretic Response to ECF Expansion and Atrial
Natriuretic Peptide (ANP) in Rats with Experimental Congestive Heart Failure
(CHF). American Society of Nephrology Renal Week 2009, San Diego,
California, October 27-November 1, 2009. (Poster).
69.
Bishara B., Abu-Salah N., Ramadan R., Goltsman I., Awad H., Karram T., Winaver J.
Hoffman A., and Abassi Z. Pneumoperitoneum aggravates renal function in
decompensated, but not compensated experimental congestive heart failure. The
XXVI Annual Meeting of the Israel Group for Heart Research Subsection of the
ISHR - International Society for Heart Research European Section. Haifa, 25
Feb, 2010. (Oral).
Zaid A. Abassi, D.Sc.
32